Business Description
Medesis Pharma SA
ISIN : FR0010844464
Share Class Description:
STU:76D: Ordinary SharesCompare
Compare
Traded in other countries / regions
ALMDP.France76D.Germany IPO Date
2022-02-07Description
Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | -2.34 | |||||
| Debt-to-Equity | -0.27 | |||||
| Debt-to-EBITDA | -0.31 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -24.12 | |||||
| Beneish M-Score | -6.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.3 | |||||
| 3-Year EBITDA Growth Rate | -54.5 | |||||
| 3-Year EPS without NRI Growth Rate | -58.3 | |||||
| 3-Year Book Growth Rate | -22.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.95 | |||||
| 9-Day RSI | 57.57 | |||||
| 14-Day RSI | 48.77 | |||||
| 6-1 Month Momentum % | -69.6 | |||||
| 12-1 Month Momentum % | -59.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | |||||
| Quick Ratio | 0.34 | |||||
| Cash Ratio | 0.01 | |||||
| Days Inventory | 18.59 | |||||
| Days Sales Outstanding | 1.22 | |||||
| Days Payable | 134.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -888.33 | |||||
| Operating Margin % | -1409.67 | |||||
| Net Margin % | -1319.67 | |||||
| ROA % | -213.42 | |||||
| ROIC % | -825.76 | |||||
| 3-Year ROIIC % | -2019.73 | |||||
| ROC (Joel Greenblatt) % | -3277.84 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.18 | |||||
| PS Ratio | 6.06 | |||||
| EV-to-EBIT | -0.82 | |||||
| EV-to-EBITDA | -0.88 | |||||
| EV-to-Revenue | 11.3 | |||||
| Earnings Yield (Greenblatt) % | -121.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medesis Pharma SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.3 | ||
| EPS (TTM) (€) | -0.84 | ||
| Beta | 0 | ||
| Volatility % | 80.68 | ||
| 14-Day RSI | 48.77 | ||
| 14-Day ATR (€) | 0.031439 | ||
| 20-Day SMA (€) | 0.34315 | ||
| 12-1 Month Momentum % | -59.98 | ||
| 52-Week Range (€) | 0.297 - 1.85 | ||
| Shares Outstanding (Mil) | 4.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medesis Pharma SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medesis Pharma SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medesis Pharma SA Frequently Asked Questions
What is Medesis Pharma SA(STU:76D)'s stock price today?
The current price of STU:76D is €0.39. The 52 week high of STU:76D is €1.85 and 52 week low is €0.30.
When is next earnings date of Medesis Pharma SA(STU:76D)?
The next earnings date of Medesis Pharma SA(STU:76D) is .
Does Medesis Pharma SA(STU:76D) pay dividends? If so, how much?
Medesis Pharma SA(STU:76D) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers